In particular, the inhibitors of PD1/PD‐L1 signaling has shown a good efficacy and a favorable toxicity profile in heavily pre‐treated HL and non‐Hodgkin lymphoma patients, with almost 70% of patients affected by Hodgkin disease reaching a response, including those who already underwent to ASCT and/or BV treatment.7, 8, 9, 10, 11, 18, 19. The gene discussed is CD274; the disease is Hodgkins lymphoma.